We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
The Paediatric Rheumatology Unit (PRU) at Vall d’Hebron University Hospital sits within the Rheumatology Department and is tasked with specialist care of locomotive system inflammatory disorders and other autoimmune diseases affecting paediatric patients. It consists of two rheumatology specialists with specific training in paediatric rheumatology disorders, Dr Estefanía Moreno Ruzafa and Dr Mireia López Corbeto, a specialist in Paediatrics with specific training in paediatric rheumatology, Dr Laia Martínez Mitjana, and a nurse specialising in rheumatic disorders in children, Julia Vivancos Pons.
The Paediatric Rheumatology Unit has always been a centre of reference within our Rheumatology Department. We have a close relationship with other paediatric units with the aim of setting up common strategies for diagnosing, treating and monitoring our patients.
This pathology has no cure, however, owing to the muscle and bone involvement that patients are afflicted with, it is important for them to adopt an appropriate diet and exercise to avoid becoming overweight or obese. This will reduce overloading of the joints and help in part to minimise feelings of fatigue while maximising functionality.
Dr Jou. Dr Arroyo and Primary Health Care (CAP) Infirmary.
Autism spectrum disorder is a neurodevelopmental condition with an estimated lifetime prevalence of 1%. Basic symptoms include a lack of social communication, restricted or repetitive interests and activities, and sensorial anomalies starting during early childhood.
Autism was described for the first time in 1943 by the child psychiatrist Leo Kanner. Currently, according to the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), the term Autism Spectrum Disorders refers to all those conditions that involve a lack of social communication, restricted or repetitive interests and activities, and sensorial anomalies starting during early childhood. All these conditions start to appear in early childhood even if they do not fully manifest until the person’s limited capacities stop them from responding to social needs.
Depending on the severity of the symptoms and the level of assistance required by the person, three different levels of intensity have been described (Level 1: requires help, Level 2: requires significant help, Level 3: requires large amount of help). It is important to determine whether the person also has an intellectual disability or language difficulties, if they are linked to a known medical or genetic pathology or environmental factor, if they are associated with another mental or behavioural neurological development condition, and if they are associated with autistic catatonia.
Genetics plays a fundamental role in the aetiology of autism spectrum disorders, together with pre-labour and neo-natal risk factors.
The common symptoms of all autistic spectrum disorders are:
Issues with socio-emotional reciprocity, non-verbal communication, and the development, maintenance and understanding of social relationships. And then, at least two of the following:
a) stereotyped or repetitive movements, use of objects, or speech.
b) cognitive rigidity
c) restricted interests and
d) hyper- or hypo-reactivity to sensorial stimulus or an unusual interest in the sensorial aspects of their surroundings
Autism spectrum disorders can be observed in people from around the world from all types of racial, ethnic and socio-economic groups. This disorder occurs 4 times more frequently in boys than in girls.
Diagnosis is based on observation by a child psychiatrist and paediatric neurologist.
An evaluation by a multidisciplinary team is also recommended. It is necessary to include an evaluation of the individual, an interview with his or her carers or other informants, information from the school or workplace, and to perform a cognitive and linguistic evaluation. Furthermore, a medical examination (blood and genetic tests and CAT scan) should be carried out in cases where a specific aetiology is suspected. Genetic tests can detect an aetiological cause in up to approximately 10% of cases.
At this stage, there is not enough scientific evidence to routinely recommend a specific pharmaceutical drug to address the symptoms of ASD. However, there are effective pharmaceutical drugs to treat the medical or psychiatric comorbidities that commonly occur with these disorders.
It is important to begin psychotherapeutic treatment as soon as possible, as well as to adopt educational strategies in the classroom in line with the seriousness of the psychiatric disorder.
Early detection, psychotherapeutic treatment and various educational approaches substantially improve the learning and social behaviour of the person affected, helping them to have an everyday quality of life with a certain degree of autonomy and independence.
Research into the brain’s structure and connectivity in parallel with genetic studies is paving the way towards being about to think more about effective treatments for this disorder. In fact, there are currently various clinical trials under way whose therapeutic target is the basic symptoms of ASD.
There is a series of clinical trials that can help rule out other associated presentations or a specific aetiology such as electroencephalography and CAT scans, as well as analytic tests to rule out metabolic illnesses. A genetic test is required if there are suspicions of a specific genetic alteration.
Visits to the paediatrician to monitor the evolution of a healthy child are fundamental for early detection.
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.